Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 1;11(19):3103.
doi: 10.3390/cells11193103.

Reprogramming T-Cell Metabolism for Better Anti-Tumor Immunity

Affiliations
Review

Reprogramming T-Cell Metabolism for Better Anti-Tumor Immunity

Yu Ping et al. Cells. .

Abstract

T cells play central roles in the anti-tumor immunity, whose activation and differentiation are profoundly regulated by intrinsic metabolic reprogramming. Emerging evidence has revealed that metabolic processes of T cells are generally altered by tumor cells or tumor released factors, leading to crippled anti-tumor immunity. Therefore, better understanding of T cell metabolic mechanism is crucial in developing the next generation of T cell-based anti-tumor immunotherapeutics. In this review, we discuss how metabolic pathways affect T cells to exert their anti-tumor effects and how to remodel the metabolic programs to improve T cell-mediated anti-tumor immune responses. We emphasize that glycolysis, carboxylic acid cycle, fatty acid oxidation, cholesterol metabolism, amino acid metabolism, and nucleotide metabolism work together to tune tumor-reactive T-cell activation and proliferation.

Keywords: T cell; T cell metabolism; anti-tumor function; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
T-cell metabolism in the TME. The nutrients (glucose, fatty acids, and amino acids) in the TME are lacking due to tumor cells or immunosuppressive cells, leading to abnormal metabolism of T cells. Glucose and fatty acids are used in large quantities by tumor cells for proliferation, while the metabolism of glucose and fatty acids is restricted in the T cells that infiltrated the TME to reduced anti-tumor response. Immune checkpoints (PD-1 and CTLA-4) also inhibit glycolysis in the T cells that infiltrated the TME. ROS, kynurenine, PUFA, and OXLDL are enriched in TME to induce T cell ferroptosis and exhaustion. Hypoxia and exosome in TME inhibit PGC1α activation to damage T-cell anti-tumor function. Cysteine, arginine, and methionine are competitively ingested by tumor cells or monocytes to inhibit the T-cell anti-tumor response. ATP in TME is hydrolyzed by CD39 and CD73 to produce adenosine, which decreases the T-cell anti-tumor function through A2AR. Accumulated cholesterol in TME inhibits T-cell function through ER stress, and increased cholesterol esterification in T cells restricts the T-cell anti-tumor response. 5-HTP, 5-hydroxytryptophan—A2AR, A2A receptor—ER, endoplasmic reticulum—IDO, indoleamine 2,3-dioxygenase—OXLDL, oxidized low-density lipoproteins—PGC1α, PPAR-γ co-activator 1α—PUFA, poly-unsaturated fatty acids—ROS, reactive oxygen species—SAM, s-adenosylmethionine—TME, tumor microenvironment.
Figure 2
Figure 2
Metabolic intervention strategy for improving the anti-tumor response of T cells. The interventions of glucose, lipid, amino acid, and nucleotide metabolism have been used to enhance T-cell anti-tumor responses. A2AR, A2A receptor—IDO, indoleamine 2,3-dioxygenase—LDH, Lactate dehydrogenase—PGC1α, PPAR-γ co-activator 1α.

References

    1. Smyth M.J., Teng M.W. 2018 Nobel Prize in physiology or medicine. Clin. Transl. Immunol. 2018;7:e1041. doi: 10.1002/cti2.1041. - DOI - PMC - PubMed
    1. Korman A.J., Garrett-Thomson S.C., Lonberg N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat. Rev. Drug Discov. 2021;21:509–528. doi: 10.1038/s41573-021-00345-8. - DOI - PubMed
    1. Dammeijer F., van Gulijk M., Mulder E.E., Lukkes M., Klaase L., van den Bosch T., van Nimwegen M., Lau S.P., Latupeirissa K., Schetters S., et al. The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes. Cancer Cell. 2020;38:685–700.e8. doi: 10.1016/j.ccell.2020.09.001. - DOI - PubMed
    1. Lozano A.X., Chaudhuri A.A., Nene A., Bacchiocchi A., Earland N., Vesely M.D., Usmani A., Turner B.E., Steen C.B., Luca B.A., et al. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. Nat. Med. 2022;28:353–362. doi: 10.1038/s41591-021-01623-z. - DOI - PMC - PubMed
    1. Watson R.A., Tong O., Cooper R., Taylor C.A., Sharma P.K., de Los Aires A.V., Mahé E.A., Ruffieux H., Nassiri I., Middleton M.R., et al. Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8 T cell clone size and cytotoxicity. Sci. Immunol. 2021;6:eabj8825. doi: 10.1126/sciimmunol.abj8825. - DOI - PMC - PubMed

Publication types